Yamada S, Takada K, Tsuchida S, Teramoto A, Shishiba Y
Department of Neurosurgery, Toranomon Hospital, Tokyo, Japan.
Endocr J. 1996 Jun;43(3):335-8. doi: 10.1507/endocrj.43.335.
Human interferon beta (IFN-beta) has been used for the treatment of patients with benign and malignant astrocytomas. The effect of IFN-beta on pituitary function, however, has not been precisely evaluated before. In this study the serum levels of various anterior pituitary hormones including GH, PRL, ACTH, and TSH were measured to determine the effects of IFN-beta on pituitary endocrine function in 19 consecutive glioma patients receiving IFN-beta. Daily doses of 3 x 10(6) U of IFN-beta were administered as a 30-min intravenous drip infusion beginning at 0800 h every morning during the first week and then 4 times a week for additional 6 weeks. Blood samples were taken on the day prior to administration as controls (0900 h and 1500 h), and on the first day of administration (0900 h and 1500 h) and after 7 days of administration (0900 h) in order to determine the acute and chronic or integrated effects of IFN-beta on the above pituitary hormones. No significant change in serum concentrations of any of the pituitary hormones examined was observed, suggesting that human natural IFN-beta used for the treatment of gliomas has no significant effect on the secretion of these hormones from the pituitary in these patients.
人干扰素β（IFN-β）已用于治疗良性和恶性星形细胞瘤患者。然而，IFN-β对垂体功能的影响此前尚未得到精确评估。在本研究中，对19例连续接受IFN-β治疗的胶质瘤患者，测定了包括生长激素（GH）、催乳素（PRL）、促肾上腺皮质激素（ACTH）和促甲状腺激素（TSH）在内的各种垂体前叶激素的血清水平，以确定IFN-β对垂体内分泌功能的影响。IFN-β的日剂量为3×10⁶U，在第一周每天早上08:00开始进行30分钟的静脉滴注，然后在接下来的6周内每周给药4次。在给药前一天（09:00和15:00）、给药第一天（09:00和15:00）以及给药7天后（09:00）采集血样，以确定IFN-β对上述垂体激素的急性、慢性或综合影响。未观察到所检测的任何垂体激素血清浓度有显著变化，这表明用于治疗胶质瘤的人天然IFN-β对这些患者垂体中这些激素的分泌没有显著影响。
